| 研究报告 |
|
|
|
|
| HeLa细胞中INI1通过与E2A作用下调CD117 |
| 范彦会1, 韩秋悦2,3, 王雅丽1, 韩春雨1 |
1. 河北科技大学生物科学与工程学院 石家庄 050018;
2. 石家庄市第九医院 石家庄 050100;
3. 河北医科大学研究生学院 石家庄 050017 |
|
| INI1 Down-regulates CD117 in HeLa by Interacting with E2A |
| FAN Yan-hui1, HAN Qiu-yue2,3, WANG Ya-li1, HAN Chun-yu1 |
1. College of Biological Sciences and Engineering, Hebei University of Science and Technology, Shijiazhuang 050018, China;
2. Ninth Hospital of Shijiazhuang, Shijiazhuang 050100, China;
3. Graduate School, Hebei Medical University, Shijiazhuang 050017, China |
引用本文:
范彦会, 韩秋悦, 王雅丽, 韩春雨. HeLa细胞中INI1通过与E2A作用下调CD117[J]. 中国生物工程杂志, 2011, 31(11): 31-37.
FAN Yan-hui, HAN Qiu-yue, WANG Ya-li, HAN Chun-yu. INI1 Down-regulates CD117 in HeLa by Interacting with E2A. China Biotechnology, 2011, 31(11): 31-37.
链接本文:
https://manu60.magtech.com.cn/biotech/CN/
或
https://manu60.magtech.com.cn/biotech/CN/Y2011/V31/I11/31
|
|
[1] Cetin N, Dienel G, Gokden M. CD117 expression in glial tumors. J Neurooncol, 2005, 75(2):195-202.
[2] Luo L, Zeng J, Liang B, et al. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Exp Mol Pathol, 2011,91(2):596-602.
[3] Kitamura Y, Hirotab S. Kit as a human oncogenic tyrosine kinase. Cell Mol Life Sci, 2004, 61(23): 2924-2931.
[4] Satzger I, Schaefer T, Kuettler U, et al. Analysis of c-KIT expression and KIT gene mutation in human mucosal melanomas. Br J Cancer, 2008, 99(12):2065-2069.
[5] Smalley K S, Sondak V K, Weber J S. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas. Histol Histopathol, 2009, 2(5): 643-650.
[6] Ali S. Role of c-kit/SCF in cause and treatment of gastrointestinal stromal tumors (GIST). Gene, 2007,401(1-2):38-45.
[7] Vandenbark G R, Chen Y, Friday E, et al. Complex regulation of human c-kit transcription by promoter repressors, activators, and specific myb elements. Cell Growth Differ, 1996, 7(10):1383-1392.
[8] Hassan H T. c-Kit expression in human normal and malignant stem cells prognostic and therapeutic implications. Leuk Res, 2009, 33(1): 5-10.
[9] Spinello I, Quaranta M T, Pasquini L, et al. PLZF-mediated control on c-kit expression in CD34(+) cells and early erythropoiesis. Oncogene, 2009, 28(23): 2276-2288.
[10] Lécuyer E, Herblot S, Saint-Denis M, et al. The SCL complex regulates c-kit expression in hematopoietic cells through functional interaction with Sp1. Blood, 2002, 100(7):2430-2440.
[11] Vitelli L, Condorelli G, Lulli V. A pentamer transcriptional complex including tal-1 and retinoblastoma protein downmodulates c-kit expression in normal erythroblasts. Mol Cell Biol, 2000, 20(14):5330-5542.
[12] Pfister S M, Korshunov A, Kool M, et al. Molecular diagnostics of CNS embryonal tumors. Acta Neuropathol, 2010, 120(5):553-566.
[13] Isakoff M S, Sansam C G, Tamayo P, et al. Inactivation of the Snf5 tumor suppressor stimulates cell cycle progression and cooperates with p53 loss in oncogenic transformation. Proc Natl Acad Sci USA, 2005, 102(49): 17745-17750.
[14] Stojanova A, Penn L Z, The role of INI1/hSNF5 in gene regulation and cancer. Biochem Cell Biol, 2009, 87(1): 163-177.
[15] Parissi V, Caumont A, de Soultrait V R, et al. Inactivation of the SNF5 transcription factor gene abolishes the lethal phenotype induced by the expression of HIV-1 integrase in yeast. Gene, 2010, 247(1-2): 129-136.
[16] Maroun M, Delelis O, Coadou G, et al. Inhibition of early steps of HIV-1 replication by SNF5/Ini1. J Biol Chem, 2006, 281(32): 22736-22743.
[17] Wu D Y, Kalpana G V, Goff S P, et al. Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol, 1996, 70(9): 6020-6028.
[18] Cheng S W, Davies K P, Yung E, et al. c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function. Nat Genet, 1999, 22(1): 102-105.
[19] Lee D, Sohn H, Kalpana G V, et al. Interaction of E1 and hSNF5 proteins stimulates replication of human papillomavirus DNA. Nature, 1999, 399(6735): 487-491.
[20] DelBove J, Kuwahara Y, Mora-Blanco E L, et al. Inactivation of SNF5 cooperates with p53 loss to accelerate tumor formation in Snf5(+/-);p53(+/-) mice. Mol Carcinog, 2009, 48(12): 1139-1148.
[21] Yamamoto H, Kohashi K, Tsuneyoshi M, et al. Heterozygosity Loss at 22q and Lack of INI1 Gene Mutation in Gastrointestinal Stromal Tumor. Pathobiology, 2011, 78(3):132-139.
[22] Han C, Liu H, Liu J, et al. Human Bex2 interacts with LMO2 and regulates the transcriptional activity of a novel DNA-binding complex. Nucleic Acids Res, 2005, 33(20): 6555-6565.
[23] Zhang Z K, Davies K P, Allen J, et al. Cell cycle arrest and repression of cyclin D1 transcription by INI1/hSNF5. Mol Cell Biol, 2002, 22(16): 5975-5988.
[24] Bochar D A, Wang L, Beniya H, et al. BRCA1 is associated with a human SWI/SNF-related complex: linking chromatin remodeling to breast cancer. Cell, 2000, 102(2): 257-265.
[25] Slattery C, Ryan M P, McMorrow T. E2A proteins: regulators of cell phenotype in normal physiology and disease. Int J Biochem Cell Biol, 2008, 40(8): 1431-1436.
[26] Sobrado V R, Moreno-Bueno G, Cubillo E, et al. The class I bHLH factors E2-2A and E2-2B regulate EMT. J Cell Sci, 2009, 122(7): 1014-1024.
[27] Kondi-Pafiti A, Arkadopoulos N, Gennatas C, et al. Expression of c-kit in common benign and malignant breast lesions. Tumori, 2010, 96(6):978-984.
|
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
